

IN THE SPECIFICATION:

Please amend the specification as follows:

In the "Brief Description of the Figures," at pages 8 and 9;

at page 8, line 29, please delete "1A" and substitute therefor --1A-1 and 1A-2--.

at page 9, line 1, please delete "1B" and substitute therefor --1B-1 and 1B-2--.

at page 9, line 6, please delete "2A" and substitute therefor --2A-1 and 2A-2--.

at page 9, line 10, please delete "2B" and substitute therefor --2B-1 and 2B-2--.

at page 9, line 27, please delete "5" and substitute therefor --5A and 5B--.

at page 10, line 1, please delete "6" and substitute therefor --6A and 6B--.

at page 10, line 4, please delete "7" and substitute therefor --7A and 7B--.

at page 10, line 16, please delete "11" and substitute therefor --11A to 11G--.

at page 10, line 22, please delete "13" and substitute therefor --13A and 13B--.

at page 12, line 16, please delete "17" and substitute therefor --17A to 17D--.

at page 12, line 25, please delete "18" and substitute therefor --18A and 18B--.

at page 13, line 7, please delete "20" and substitute therefor --20A-1 to 20A-6--.

IN THE CLAIMS:

Please amend the claims as follows:

26. (Twice Amended) A method for inhibiting a p30 polypeptide-mediated cellular response comprising

(a) providing a composition comprising an HVEM or LT β R polypeptide that binds to a p30 polypeptide[, HVEM or LT β R] and that inhibits binding of a cell surface expressed p30 polypeptide to a cell surface expressed HVEM or LT β R, said p30 polypeptide having an apparent molecular weight of about 30kDa as determined by SDS-PAGE and an isoelectric charge (pI) of [between] about pI 7 [to about] _ pI 8.5 and that binds HVEM or LT β R; and

(b) contacting the cell expressing the cell surface expressed p30 polypeptide or the cell surface expressed HVEM or LT β R with an amount of the composition comprising an HVEM or LT β R polypeptide sufficient to inhibit a p30 polypeptide-mediated cellular response, said cellular response comprising inhibition of rheumatoid arthritis.